![]() |
Halaven(TM) (Eribulin) Receives European Commission Approval For Advanced Breast Canc
Eisai announced today that it has received approval from the European Commission for Halaven(TM) (Eribulin) for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease...
More... |
| All times are GMT -7. The time now is 02:04 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021